What SEC filings does Pediatrix Medical Group, Inc. submit to the SEC?

Pediatrix Medical Group, Inc. (MD) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about MD?

A Form 4 for MD discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Pediatrix Medical Group, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for MD?

The 10-K is Pediatrix Medical Group, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all MD SEC filings directly on EDGAR?

You can view all historical Pediatrix Medical Group, Inc. filings on the SEC EDGAR company page for MD. Each filing card on this page links directly to the original SEC document.

How often does Pediatrix Medical Group, Inc. file with the SEC?

Pediatrix Medical Group, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling MD shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

MD SEC Filing News — Pediatrix Medical Group, Inc.

Latest SEC filings for Pediatrix Medical Group, Inc. (MD) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-14.

Pediatrix Medical Group, Inc., together with its subsidiaries, provides newborn, maternal-fetal, and other pediatric subspecialty care services in the United States. The company offers clinical care to babies born prematurely or with complications within specific units at hospitals, primarily NICUs, through its network of affiliated neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; and inpatient and office-based clinical care to expectant mothers an…

Sector: Healthcare Industry: Medical Care Facilities Market Cap: $2.2B

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

What you're looking at: Each item below is parsed from an actual SEC filing submitted by Pediatrix Medical Group, Inc.. Form 4 = confirmed insider transaction · Form 144 = proposed sale notice · 8-K = material event (earnings, M&A, leadership change, etc.) · 10-Q / 10-K = quarterly / annual report.

MD Filing Activity Snapshot 2026-06-10 — 2026-09-14

Insider Transactions (Form 4)

0 buys vs 0 sells

Insider buying and selling activity is balanced in this period.

Largest Form 144 Filing

$572.6K

Mary Ann E Moore · 2026-09-14

21,335 shares · Form 144

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 12 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 12 filings in this group are Form 4s for Pediatrix Medical Group, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 12 insider filings shown, the breakdown is 9 compensation award, 2 disposition to issuer and 1 gift. None of the classified filings involved a discretionary open-market trade, so this period says nothing about what insiders think of the price.

What each transaction type means

Compensation award ×9: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Disposition to issuer ×2: Shares were surrendered to or repurchased by the issuer rather than sold to other investors.
Gift ×1: Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Form 4 Disposition to issuer Tax / Compensation Filing 2026-09-14

MD insider Form 4 filed for equity award, exercise, or tax withholding

Linynsky Laura A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were surrendered to or repurchased by the issuer rather than sold to other investors.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer	6,000	$26.82	$160.9K

Filing: Form 4 (Insider Transaction) Insider: Linynsky Laura A (Director) Shares: 6,000

View on SEC EDGAR → Open Filing Document →

Form 4 Disposition to issuer Tax / Compensation Filing 2026-08-18

MD insider Form 4 filed for equity award, exercise, or tax withholding

Young Sylvia Jean (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were surrendered to or repurchased by the issuer rather than sold to other investors.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`D`	Disposition to issuer	18,500	$26.62	$492.5K

Filing: Form 4 (Insider Transaction) Insider: Young Sylvia Jean (Director) Shares: 18,500

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

MD insider Form 4 filed for equity award, exercise, or tax withholding

McEachin Thomas (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	472	$26.50	$12.5K

Filing: Form 4 (Insider Transaction) Insider: McEachin Thomas (Director) Shares: 472

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

MD insider Form 4 filed for equity award, exercise, or tax withholding

Weis Shirley A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	472	$26.50	$12.5K

Filing: Form 4 (Insider Transaction) Insider: Weis Shirley A (Director) Shares: 472

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

MD insider Form 4 filed for equity award, exercise, or tax withholding

Starcher John M. Jr. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	472	$26.50	$12.5K

Filing: Form 4 (Insider Transaction) Insider: Starcher John M. Jr. (Director) Shares: 472

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

MD insider Form 4 filed for equity award, exercise, or tax withholding

Linynsky Laura A (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	472	$26.50	$12.5K

Filing: Form 4 (Insider Transaction) Insider: Linynsky Laura A (Director) Shares: 472

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

MD insider Form 4 filed for equity award, exercise, or tax withholding

Newman Kurt Douglas (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	472	$26.50	$12.5K

Filing: Form 4 (Insider Transaction) Insider: Newman Kurt Douglas (Director) Shares: 472

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

MD insider Form 4 filed for equity award, exercise, or tax withholding

Rucker Michael A. (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	472	$26.50	$12.5K

Filing: Form 4 (Insider Transaction) Insider: Rucker Michael A. (Director) Shares: 472

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

MD insider Form 4 filed for equity award, exercise, or tax withholding

Young Sylvia Jean (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	472	$26.50	$12.5K

Filing: Form 4 (Insider Transaction) Insider: Young Sylvia Jean (Director) Shares: 472

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-14

MD insider Form 4 filed for equity award, exercise, or tax withholding

SANSONE GUY P (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	472	$26.50	$12.5K

Filing: Form 4 (Insider Transaction) Insider: SANSONE GUY P (Director) Shares: 472

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-24

MD insider Form 4 filed for equity award, exercise, or tax withholding

Haddock David (EVP, GC & Corp Sec) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award	20,036	—	—
`A`	Compensation award derivative · Performance Share Unit	51,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Haddock David (EVP, GC & Corp Sec) Shares: 20,036

View on SEC EDGAR → Open Filing Document →

Form 4 Gift Tax / Compensation Filing 2026-06-10

MD insider Form 4 filed for equity award, exercise, or tax withholding

Moore Mary Ann E (EVP, GC, Chief Admin Off & Sec) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were transferred as a gift, typically for estate or charitable planning. No sale into the market took place.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`G`	Gift	18,407	—	—
`G`	Gift	18,407	—	—

Filing: Form 4 (Insider Transaction) Insider: Moore Mary Ann E (EVP, GC, Chief Admin Off & Sec) Shares: 36,814

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 4 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Pediatrix Medical Group, Inc. has 4 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-14

MD Form 144 filed for proposed insider sale by Mary Ann E Moore (21,335 shares) ~$572.6K

Mary Ann E Moore filed a Form 144 with the SEC indicating intent to sell MD (Pediatrix Medical Group, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Mary Ann E Moore Shares: 21,335 Est. Value: $572.6K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-14

MD Form 144 filed for proposed insider sale by Mary Ann E Moore (9,260 shares) ~$246.4K

Filing: Form 144 (Proposed Sale Notice) Insider: Mary Ann E Moore Shares: 9,260 Est. Value: $246.4K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-10

MD Form 144 filed for proposed insider sale by Laura Linynsky (6,000 shares) ~$160.7K

Laura Linynsky filed a Form 144 with the SEC indicating intent to sell MD (Pediatrix Medical Group, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Laura Linynsky Shares: 6,000 Est. Value: $160.7K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-08-14

MD Form 144 filed for proposed insider sale by Sylvia Young (18,500 shares) ~$491.9K

Sylvia Young filed a Form 144 with the SEC indicating intent to sell MD (Pediatrix Medical Group, Inc.) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Sylvia Young Shares: 18,500 Est. Value: $491.9K

View on SEC EDGAR → Open Filing Document →

Material Events 3 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 3 in this period for Pediatrix Medical Group, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-04

MD filed 8-K — material company event

Pediatrix Medical Group, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-07-24

MD filed 8-K — material company event

Pediatrix Medical Group, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-07-15

MD filed 8-K — material company event

Pediatrix Medical Group, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Pediatrix Medical Group, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-04

MD filed Quarterly Report (10-Q)

Pediatrix Medical Group, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Pediatrix Medical Group, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on MD. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — MD SEC Filings

More Tools for MD

MD Full Stock Analysis MD Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper MD analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the MD stock analysis page.

MD Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer